Alpha-substituted arylsulphonamido hydroxamic acids as TNF-alpha and matrix metalloproteinase inhibitors

Particularly the invention relates to the compounds of formula I (I) wherein Ar represents carbocyclic aryl, heterocyclic aryl or biaryl; R1 represents lower alkyl, cycloalkyl, aryl-lower alkyl, lower alkoxy-lower alkyl, aryl, cycloalkyl-lower alkyl, halo-lower alkyl; R2 represents hydrogen or lower...

Full description

Saved in:
Bibliographic Details
Main Author DAVID THOMAS PARKER
Format Patent
LanguageEnglish
Published 26.08.1999
Edition6
Subjects
ACYCLIC OR CARBOCYCLIC COMPOUNDS
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Particularly the invention relates to the compounds of formula I (I) wherein Ar represents carbocyclic aryl, heterocyclic aryl or biaryl; R1 represents lower alkyl, cycloalkyl, aryl-lower alkyl, lower alkoxy-lower alkyl, aryl, cycloalkyl-lower alkyl, halo-lower alkyl; R2 represents hydrogen or lower alkyl; R3 and R4 represent independently hydrogen, lower alkyl, lower alkoxy, halo, hydroxy, acyloxy, lower alkoxy-lower alkoxy, trifluoromethyl or cyano; or R3 and R4 together represent lower allylenedioxy; n represents an integer from 1 to 5; pharmaceutically acceptable prodrug derivatives; and pharmaceutically acceptable salts thereof; methods for preparation thereof; pharmaceutical compositions comprising said compounds; and a method of inhibiting TNF-alpha activity and matrix-degrading metalloproteinases in mammals using such compounds.
Bibliography:Application Number: AU1140697